Kallyope and Novo Nordisk announce collaboration to discover novel therapeutics for obesity and diabetes
- Details
- Category: Novo Nordisk
Kallyope, Inc and Novo Nordisk A/S today announced that they have entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes. Kallyope will receive an upfront payment and research support for activities conducted in the collaboration. Under the terms of the agreement, Novo Nordisk has an option to license exclusive worldwide rights to develop and commercialise up to six products discovered in the collaboration.
Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
- Details
- Category: Novartis
Alcon, the global leader in eye care and a division of Novartis, unveils new data showing significantly improved near and intermediate distance vision with the AcrySof IQ PanOptix intraocular lens (IOL) compared to the ZEISS AT LISA®* tri 839MP IOL. These findings further strengthen the value of the PanOptix IOL ENLIGHTENTM optical technology, to provide enhanced image quality and more comfortable near to intermediate vision setting the AcrySof IQ PanOptix IOL apart from other trifocal IOLs.
New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the final analysis of the CLL11 study evaluating Gazyva®/Gazyvaro® (obinutuzumab)-based treatment in previously untreated chronic lymphocytic leukaemia (CLL) which will be presented during the Presidential Symposium at the 23rd European Hematology Association (EHA) Annual Congress, 14 - 17 June, in Stockholm.
Pfizer announces extension of Zithromax® Antibiotic Donation Program through 2025 to help eliminate world's leading infectious cause of blindness
- Details
- Category: Pfizer
Pfizer Inc. will extend its donation of the antibiotic Zithromax® (azithromycin) to the International Trachoma Initiative through 2025, building on the company's 20-years of work to help eliminate the world's leading infectious cause of blindness. Approximately 163 million people are at risk of developing the disease and this recommitment ensures that Pfizer, through the International Trachoma Initiative (ITI), will continue to provide trachoma endemic countries with donated antibiotics that are a critical component of the global strategy to eliminate this neglected tropical disease (NTD).
Update on Phase III clinical trials of lanabecestat for Alzheimer's disease
- Details
- Category: AstraZeneca
AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer's disease. The decision is based on recommendations by an independent data monitoring committee (IDMC), which concluded that both the AMARANTH trial, in early Alzheimer's disease, and the DAYBREAK-ALZ trial, in mild Alzheimer's disease dementia, were not likely to meet their primary endpoints upon completion and therefore should be stopped for futility.
Amgen, Oklahoma Health Care Authority and University of Oklahoma's Pharmacy Management Consultants partner to improve medicaid outcomes
- Details
- Category: Amgen
The Oklahoma Health Care Authority (OHCA), Pharmacy Management Consultants (PMC) and Amgen (NASDAQ:AMGN) announced a new collaborative agreement to help improve clinical outcomes, experience and satisfaction for Oklahoma's 796,000 SoonerCare (Oklahoma Medicaid) members. Results from the projects also could lay the groundwork for innovative ways to look at patient outcomes and measures for medication reimbursement.
FDA grants Priority Review to Roche’s Hemlibra for people with haemophilia A without factor VIII inhibitors
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Hemlibra® (emicizumab-kxwh) for adults and children with haemophilia A without factor VIII inhibitors. The sBLA is based on data from the phase III HAVEN 3 study.
More Pharma News ...
- Pfizer to expand venture investing with $600 million commitment to Pfizer Ventures
- Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
- The Pfizer Foundation announces $5 million in grants to support women and families
- Amgen Foundation and Harvard team up to offer free online science education platform
- Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
- AstraZeneca heads to 2018 ASCO Annual Meeting with its diversified oncology portfolio and next-generation pipeline
- Spiolto® Respimat® enables greater physical activity in people living with Chronic Obstructive Pulmonary Disease